Novartis shares fell 10.89% on Tuesday to close at CHF 111.80, the Swiss drugmaker's worst day on record, after the late-stage HARBOR trial of del-desiran, the lead drug from its roughly $12bn takeover of Avidity Biosciences, missed its main goal. The miss came four days after the heart drug pelacarsen fell short in its own Phase III outcomes study.
Novartis, 8 September
- -10.89% fall in the share price on the day
- CHF 111.80 closing price in Zurich
- -14.9% over three sessions from CHF 131.32
What the HARBOR Trial Showed
Novartis said in an ad hoc statement on Tuesday that HARBOR did not show a statistically significant improvement over placebo on its primary endpoint, video hand opening time. That is a measure of hand myotonia, the muscle stiffness seen in myotonic dystrophy type 1 (DM1), an inherited muscle disease.
The global, randomised, double-blind study treated about 150 people with DM1 for 54 weeks, with del-desiran or placebo given every eight weeks. Novartis said its secondary endpoints, which included grip strength, muscle testing, daily activities and a 10-metre walk or run, and its exploratory analyses showed evidence of clinical activity. Safety was generally in line with earlier data. The company published no detailed figures.
Del-desiran is an antibody oligonucleotide conjugate, or AOC: an antibody that targets muscle cells, linked to a small interfering RNA designed to break down the faulty DMPK messenger RNA behind the disease. It holds US Orphan Drug, Fast Track and Breakthrough Therapy designations.
Novartis is now reviewing the full dataset and will consult health authorities on the path forward. Chief medical officer Shreeram Aradhye said "setbacks are part of scientific progress."
By 12:17 BST the shares were down 9.4% at CHF 113.70 and on course for their worst session on record, Sharecast News reported. They lost more ground into the close.

Novartis: share price, chart and news
Why the Market Reacted So Sharply
The trial tested strategy as much as science. Novartis completed its purchase of Avidity for about $12bn in February, buying three advanced rare muscle-disease programmes and Avidity's AOC technology. Del-desiran was the most advanced of the three, and analysts had flagged the readout as particularly important for validating the deal, European Biotechnology reported.
It was also the second blow in a week. Two of the three key studies Novartis presented over the past week missed their primary goals, XTB noted, which raised questions about where the company's next growth will come from.
Novartis was the steepest faller in the STOXX Europe 600. According to XTB, the drop cut its gain for the year to under 5% and brought its price-to-earnings ratio down to about 20 times. Switzerland's SMI index fell 1.55% on the day.
Pelacarsen: The First Setback
On Friday 4 September Novartis reported that pelacarsen, which it licensed from Ionis Pharmaceuticals, had missed the primary endpoint of the Lp(a)HORIZON trial. The study enrolled 8,323 patients with raised levels of lipoprotein(a), or Lp(a), and established cardiovascular disease.
Pelacarsen lowered Lp(a) as intended but did not significantly reduce cardiovascular events in the overall study population. That was a blow to a programme aimed at a large market: Novartis says raised Lp(a) affects roughly one in five people worldwide and has no approved targeted treatment. Full results will be presented at a medical congress.
The shares slipped 1.33% on Friday and fell a further 3.18% on Monday, a drop Sharecast linked to the pelacarsen result. Including Tuesday's slide, the stock has lost 14.9% in three sessions, from CHF 131.32 at Thursday's close. In daily closing data going back to 1995, the previous worst session was a 9.8% drop on 12 March 2020.
Cardiovascular research had another setback on Monday. Novo Nordisk said it had stopped two late-stage heart-failure studies of its drug ziltivekimab early, after an independent monitoring committee judged them unlikely to produce a better result than an earlier failed trial, Reuters reported.
What Comes Next
Novartis kept its medium-term target of 5% to 6% average annual sales growth from 2025 to 2030. Its two other AOC drugs from the Avidity deal remain in play. Del-zota, for a genetic subtype of Duchenne muscular dystrophy, has been filed for accelerated approval in the US and granted priority review. Novartis also plans to meet the US Food and Drug Administration on next steps for del-brax in facioscapulohumeral muscular dystrophy, after positive early-stage biomarker data.
Investors will now watch for three things: the full HARBOR data and whatever Novartis agrees with regulators about the programme, the detailed pelacarsen results at a medical congress, and the US decision on del-zota. With two of its bigger pipeline bets set back in a week, the growth target will face closer scrutiny.
Sources
- Novartis: Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
- Novartis: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
- Sharecast News via Hargreaves Lansdown: Novartis shares tumble after second late-stage drug setback
- XTB: Novartis shares fall the most since 2020. What is behind the 10% decline?
- European Biotechnology: Novartis' $12B Avidity bet suffers Phase 3 blow
- Reuters via Euronext: Novo scraps two more heart drug trials, further dimming growth beyond obesity
- BMK News market data (delayed exchange data)








